DexCom (DXCM) Trading 7.3% Higher

Shares of DexCom, Inc. (NASDAQ:DXCM) traded up 7.3% during mid-day trading on Thursday . The stock traded as high as $58.68 and last traded at $58.60. 2,088,800 shares changed hands during trading, a decline of 22% from the average session volume of 2,665,200 shares. The stock had previously closed at $54.60.

Several analysts have recently issued reports on the company. Barclays reiterated a “hold” rating and set a $60.00 price target on shares of DexCom in a research note on Monday, January 8th. Piper Jaffray Companies reiterated a “buy” rating and set a $87.00 price target on shares of DexCom in a research note on Thursday, September 28th. Northland Securities assumed coverage on DexCom in a research note on Tuesday, September 26th. They set an “outperform” rating and a $85.00 price target for the company. Leerink Swann reiterated a “buy” rating and set a $57.00 price target (down previously from $85.00) on shares of DexCom in a research note on Friday, September 29th. Finally, Oppenheimer decreased their price target on DexCom from $92.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, September 28th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $72.31.

The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84.

In other DexCom news, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total value of $73,280.70. Following the completion of the transaction, the executive vice president now owns 65,049 shares of the company’s stock, valued at approximately $2,915,496.18. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mark G. Foletta sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $54.95, for a total value of $137,375.00. Following the completion of the transaction, the director now directly owns 4,952 shares of the company’s stock, valued at approximately $272,112.40. The disclosure for this sale can be found here. Insiders have sold a total of 38,140 shares of company stock valued at $2,158,576 in the last three months. 1.70% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. Winslow Capital Management LLC acquired a new position in DexCom in the 2nd quarter valued at approximately $117,451,000. State Street Corp raised its holdings in DexCom by 2.5% in the 2nd quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock valued at $113,374,000 after acquiring an additional 37,581 shares in the last quarter. Peregrine Capital Management LLC raised its holdings in DexCom by 24.5% in the 3rd quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock valued at $19,348,000 after acquiring an additional 77,868 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in DexCom by 3.2% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 265,019 shares of the medical device company’s stock valued at $12,967,000 after acquiring an additional 8,171 shares in the last quarter. Finally, Macquarie Group Ltd. raised its holdings in DexCom by 67.2% in the 2nd quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock valued at $17,746,000 after acquiring an additional 97,479 shares in the last quarter.

WARNING: “DexCom (DXCM) Trading 7.3% Higher” was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.themarketsdaily.com/2018/01/13/dexcom-dxcm-trading-7-3-higher.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply